AUROBINDO PHARMA
|
AUROBINDO PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 60.34 | 60.02 | 54.16 | 32.90 | 45.20 |
| CEPS(Rs) | 90.93 | 88.38 | 80.06 | 54.14 | 64.41 |
| DPS(Rs) | 4.00 | - | 4.50 | 3.00 | 9.00 |
| Book NAV/Share(Rs) | 652.39 | 562.21 | 509.35 | 458.10 | 419.46 |
| Tax Rate(%) | 31.47 | 31.24 | 27.65 | 26.21 | 21.51 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 9.81 | 10.36 | 9.77 | 7.31 | 9.17 |
| EBIT Margin(%) | 7.91 | 8.69 | 7.81 | 5.41 | 7.16 |
| Pre Tax Margin(%) | 7.35 | 7.97 | 7.33 | 5.14 | 7.05 |
| PAT Margin (%) | 5.04 | 5.48 | 5.30 | 3.79 | 5.54 |
| Cash Profit Margin (%) | 7.60 | 8.08 | 7.85 | 6.24 | 7.89 |
| Performance Ratios | |||||
| ROA(%) | 6.64 | 7.54 | 7.63 | 5.29 | 7.90 |
| ROE(%) | 9.93 | 11.15 | 11.18 | 7.50 | 11.38 |
| ROCE(%) | 12.76 | 14.39 | 13.76 | 9.39 | 12.71 |
| Asset Turnover(x) | 1.32 | 1.38 | 1.44 | 1.40 | 1.43 |
| Sales/Fixed Asset(x) | 2.59 | 2.65 | 2.84 | 2.95 | 3.24 |
| Working Capital/Sales(x) | 4.74 | 5.09 | 5.17 | 5.10 | 4.84 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.39 | 0.38 | 0.35 | 0.34 | 0.31 |
| Receivable days | 33.71 | 30.33 | 28.34 | 30.42 | 28.69 |
| Inventory Days | 59.32 | 58.44 | 55.92 | 57.65 | 63.29 |
| Payable days | 148.20 | 135.14 | 133.88 | 117.74 | 108.60 |
| Valuation Parameters | |||||
| PER(x) | 21.60 | 19.32 | 20.12 | 15.75 | 14.80 |
| PCE(x) | 14.33 | 13.12 | 13.61 | 9.57 | 10.39 |
| Price/Book(x) | 2.00 | 2.06 | 2.14 | 1.13 | 1.59 |
| Yield(%) | 0.31 | - | 0.41 | 0.58 | 1.35 |
| EV/Net Sales(x) | 2.18 | 2.11 | 2.20 | 1.17 | 1.59 |
| EV/Core EBITDA(x) | 10.02 | 9.31 | 9.98 | 7.26 | 7.94 |
| EV/EBIT(x) | 13.37 | 12.14 | 13.68 | 10.58 | 10.92 |
| EV/CE(x) | 1.61 | 1.65 | 1.77 | 0.92 | 1.11 |
| M Cap / Sales | 2.25 | 2.12 | 2.20 | 1.22 | 1.67 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 6.08 | 9.39 | 16.68 | 5.97 | -5.32 |
| Core EBITDA Growth(%) | 1.85 | 12.57 | 59.64 | -14.83 | -17.62 |
| EBIT Growth(%) | -0.50 | 18.28 | 69.62 | -19.54 | -53.88 |
| PAT Growth(%) | 0.56 | 9.93 | 64.40 | -27.18 | -50.37 |
| EPS Growth(%) | 0.54 | 10.83 | 64.62 | -27.21 | -50.36 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.20 | 0.24 | 0.21 | 0.18 | 0.10 |
| Current Ratio(x) | 1.81 | 1.85 | 1.95 | 1.87 | 2.21 |
| Quick Ratio(x) | 1.15 | 1.13 | 1.14 | 1.13 | 1.29 |
| Interest Cover(x) | 14.31 | 12.08 | 16.12 | 19.60 | 70.34 |
| Total Debt/Mcap(x) | 0.10 | 0.12 | 0.10 | 0.16 | 0.06 |
Compare Financial Ratios of peers of AUROBINDO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AUROBINDO PHARMA | ₹96,540.6 Cr | 5.5% | -1.5% | 52.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹426,662.0 Cr | 2% | -4.4% | 3.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹257,903.0 Cr | 7.1% | 2.5% | 46.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹176,306.0 Cr | 1.4% | -5.7% | 27.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,699.0 Cr | 3.6% | 8% | 4.2% | Stock Analytics | |
| CIPLA | ₹111,489.0 Cr | 2% | -0.2% | -14.3% | Stock Analytics | |
AUROBINDO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AUROBINDO PHARMA | 5.5% |
-1.5% |
52.5% |
| SENSEX | 1.8% |
2.3% |
-11.9% |
You may also like the below Video Courses
